The power and the promise of cell reprogramming: Personalized autologous body organ and cell transplantation

dc.contributor.author
Álvarez Palomo, Ana Belén
dc.contributor.author
Lucas, Michaela
dc.contributor.author
Dilley, Rodney J.
dc.contributor.author
McLenachan, Samuel
dc.contributor.author
Chen, Fred K.
dc.contributor.author
Requena Osete, Jordi
dc.contributor.author
Farrera Sal, Martí
dc.contributor.author
Lucas, Andrew
dc.contributor.author
Álvarez, Iñaki
dc.contributor.author
Jaraquemada, Dolores
dc.contributor.author
Edel, Michael John
dc.date.issued
2017-12-13T18:02:05Z
dc.date.issued
2017-12-13T18:02:05Z
dc.date.issued
2014-04-04
dc.date.issued
2017-12-13T18:02:06Z
dc.identifier
2077-0383
dc.identifier
https://hdl.handle.net/2445/118715
dc.identifier
661432
dc.identifier
26237380
dc.description.abstract
Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues.
dc.format
15 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/jcm3020373
dc.relation
Journal of Clinical Medicine, 2014, vol. 3, num. 2, p. 373-387
dc.relation
https://doi.org/10.3390/jcm3020373
dc.rights
cc-by (c) Álvarez Palomo, Ana Belén et al., 2014
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Biomedicina)
dc.subject
Bioenginyeria
dc.subject
Trasplantament d'òrgans
dc.subject
Teràpia cel·lular
dc.subject
Bioengineering
dc.subject
Transplantation of organs
dc.subject
Cellular therapy
dc.title
The power and the promise of cell reprogramming: Personalized autologous body organ and cell transplantation
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)